全基因组CRISPR-Cas9筛选鉴定BCL家族成员作为实验性胶质瘤中对瑞戈非尼反应的调节因子
该临床前研究采用全基因组CRISPR-Cas9激活和敲除筛选,鉴定瑞戈非尼反应调节因子,并在体外、离体及三种原位胶质瘤小鼠模型中验证。结果显示瑞戈非尼联合Bcl-2/Bcl-xL抑制优于单药治疗,作者认为有必要在临床试验中研究瑞戈非尼联合navitoclax。
要点
- 全基因组CRISPR-Cas9筛选鉴定出BCL2、BCL2L1等瑞戈非尼反应调节因子。
- 瑞戈非尼联合Bcl-2/Bcl-xL抑制在体外、离体和体内均优于单药。
- 作者认为有必要在临床试验中研究瑞戈非尼联合navitoclax。
核心结论
- 这项临床前研究为临床转化提供了生物学依据,作者认为有必要在临床试验中研究瑞戈非尼联合navitoclax。
研究设计与样本
- 采用全基因组CRISPR-Cas9激活和敲除筛选,随后进行遗传、药理学和功能验证。
- 通过RNA测序和DigiWest评估瑞戈非尼诱导的分子改变。
- 在三种原位胶质瘤小鼠模型(同基因SMA560/VM/Dk模型和两种异种移植模型)中研究选定的功能指导组合疗法,并对治疗后脑组织进行免疫组化。
主要发现
- 鉴定出潜在瑞戈非尼反应调节因子,包括BCL2、BCL2L1、ITGB3、FOXC1、SERAC1、ARAF和PLCE1。
- 瑞戈非尼联合Bcl-2/Bcl-xL抑制在体外、离体和体内均优于两种单药治疗。
- 鉴定出瑞戈非尼诱导的Bcl-2下游靶点趋化因子受体1(CCR1)调控作为潜在分子介质之一。
- 瑞戈非尼导致胶质瘤相关微环境中髓系细胞区室的变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Registered systemic treatment options for glioblastoma patients are limited. The phase II REGOMA trial suggested an improvement of median overall survival in progressive glioblastoma by the multi-tyrosine kinase inhibitor regorafenib. This has not been confirmed by GBM AGILE. So far, regorafenib has been administered as monotherapy or as an addition to standard of care in newly diagnosed glioblastoma. Rational combination therapies involving regorafenib might be a reasonable strategy. Here, we aimed at identifying functionally instructed combination therapies involving regorafenib. METHODS: We applied a genome-wide CRISPR-Cas9-based functional genomics target discovery approach using activation and knockout screens followed by genetic, pharmacological, functional validations. Regorafenib-induced molecular alterations were assessed by RNA sequencing and DigiWest. We investigated selected functionally instructed combination therapies in three orthotopic glioma mouse models in vivo (syngeneic SMA560/VM/Dk model and two xenograft models) and performed immunohistochemistry of post-treatment brains. RESULTS: We identified potential modifiers of regorafenib response, including BCL2, BCL2L1, ITGB3, FOXC1, SERAC1, ARAF, and PLCE1. The combination of regorafenib with Bcl-2/Bcl-xL inhibition was superior to both monotherapies alone in vitro, ex vivo, and in vivo. We identified regorafenib-induced regulations of the Bcl-2 downstream target chemokine receptor 1 (CCR1) as one potential underlying molecular mediator. Furthermore, regorafenib led to changes in the myeloid compartment of the glioma-associated microenvironment. CONCLUSIONS: This preclinical study uses a functional genomics-based target discovery approach with subsequent validations involving regorafenib. It serves as a biological rationale for clinical translation. Particularly, an investigation of the combination of regorafenib plus navitoclax within a clinical trial is warranted.
引用
- Haeusser LA, Becker H, Kuhlburger L, et al. Genome-wide CRISPR-Cas9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma. Neuro Oncol. 2025. PMID: 39756423. doi:10.1093/neuonc/noae278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。